



## Lipomics Technologies announces Agreement with GlaxoSmithKline for Access to Lipid Metabolite Research and Interpretation

WEST SACRAMENTO, Calif., July 31, 2003 – Lipomics Technologies, Inc., a privately held company that specializes in lipid metabolite research and interpretation, today announced that it has signed a Research Collaboration and Option Agreement with GlaxoSmithKline for drug discovery and diagnostic development. Under the terms of the agreement, Lipomics will evaluate the effects of drug compounds on metabolism and establish the mechanism of drug response using TrueMass® lipid analysis and customized Surveyor™ and Insight™ graphical representations of lipid metabolism. The research will involve discovery research and clinical trials of promising drugs with a focus on metabolic and cardiovascular diseases. Financial details of the agreement were not disclosed.

“Lipomics has an extremely advanced knowledge of lipid metabolism,” said Tom Anderson, Lipomics CEO. “The information we provide assists in the understanding of the effects of specific drug candidates on lipid metabolism. This can help inform the decision making process in early drug discovery.”

This collaboration will also include efforts to help identify early biomarkers of drug response and disease progression, or to identify patients likely to have adverse drug responses, thereby enhancing the efficiency and decision making process of the expensive drug discovery process.

### About Lipomics Technologies, Inc.

Lipomics develops tools for drug discovery and patient monitoring based on its proprietary technologies for lipid metabolite analysis and data interpretation. The company generates a comprehensive picture of lipid metabolism from plasma or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the resulting profiles to biochemical pathways. In partnership with pharmaceutical companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, and to develop early tests for monitoring drug response. The Company’s products and technologies include TrueMass® lipid analysis platform, Signature™ algorithms for linking lipomic profiles to biochemical pathways, Surveyor™ data visualization software, and Insight™ software for assembling metabolite concentration and enzyme flux data into a quantitative pathway map.

Certain matters contained in this press release are forward looking statements that are subject to known risks and uncertainties, which may cause the Company’s actual results,

performance or achievements to be materially different from any future results,  
performance or achievements expressed or implied by these forward-looking statements.

# # #

EDITORIAL CONTACTS:

Sarina Chohan  
(916) 371-7974  
[schohan@lipomics.com](mailto:schohan@lipomics.com)

Agency Contact

Doug Forsyth, Alchymia Communications  
(541) 482-8744  
[df@alchymiacomm.com](mailto:df@alchymiacomm.com)